Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
Splanchnic metabolism of triglycerides and other major substrates was studied in the postabsorptive state in normotriglyceridemic and hypertriglyceridemic human subjects who received (1/2) g of clofibrate four times daily for 3 wk. Transport in blood plasma of triglycerides produced in the splanchnic region was quantified by three methods: (a) measurement of the transsplanchnic gradient of (14)C-labeled triglycerides during constant intravenous infusion of [1- (14)C] palmitate (b) chemical measurement of the transplanchnic gradient in concentration of triglycerides of very low density lipoproteins; and (c) determination of clearance of (14)C-labeled triglycerides in extrasplanchnic tissues. The first method measures only triglycerides derived from free fatty acids and the last two measure total splanchnic production. In hypertriglyceridemic subjects treated with clofibrate, average rates of total splanchnic production of triglycerides and production from free fatty acids were the same as those of comparable untreated subjects despite a consistent fall in plasma triglyceride levels. The hypotriglyceridemic effect of the drug was therefore accompanied by improved disposal of triglycerides in extrasplanchnic tissues. In treated normotriglyceridemic subjects, unlike their untreated counterparts, total splanchnic production was significantly higher than production from free fatty acids. Failure of clofibrate to reduce triglyceride levels in normotriglyceridemic subjects may have been related to increased total splanchnic production, coupled with improved extrasplanchnic disposal. Systemic transport and net splanchnic uptake of free fatty acids were similar in treated and control subjects but the fraction of [1-(14)C]palmitate converted to acetoacetate in splanchnic tissues was significantly higher in treated subjects. Net splanchnic extraction of plasma amino acids that enter the glucogenic pathway via pyruvate was increased in treated subjects and their arterial concentrations were reduced.
D000005:Abdomen / Q000098:blood supply; D000090:Acetoacetates / Q000097:blood; D000284:Administration, Oral; D000328:Adult; D000596:Amino Acids / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000494:pharmacology*; D004952:Esters / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents; D007408:Intestinal Absorption; D007773:Lactates / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D010101:Oxygen Consumption; D010169:Palmitic Acids / Q000097:blood; D010743:Phospholipids / Q000097:blood; D011773:Pyruvates / Q000097:blood; D012039:Regional Blood Flow; D014280:Triglycerides / Q000097:blood
D000090:Acetoacetates; D000596:Amino Acids; D001786:Blood Glucose; D004952:Esters; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D000960:Hypolipidemic Agents; D007773:Lactates; D008079:Lipoproteins, VLDL; D010169:Palmitic Acids; D010743:Phospholipids; D011773:Pyruvates; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate